Oxolife : enhancing female fertility Oxolife is a small-size clinical-stage company focused on female fertility. We are currently developing an innovative treatment (OXO-001) to enhance female fertility success through acting on peri/post implantatory process. Additionally, OXO-001 restores ovulation. OXO-001 is a first in class drug due to its mechanism of action, solving an unmet need, since no solution drug in the embryo implantation market segment is available today. Is envisioned that the first phase II clinical trial will be completed by 2023. OXO-001 is protected by three different patents under the same umbrella which cover all the possible uses for female fertility. Oxolife’s team is leaded by Agnès Arbat, Medical Doctor (Co-founder and CEO) and Ignasi Canals, Biochemist PhD (Co-founder and CSO). Both accumulate a wide experience in the Women’s health pharmaceutical industry. The team has been supported by Clinical and Scientific Opinion Leaders from prestigious centers in fertility and R&D.